Loading…
IDEAYA Biosciences, Inc. is projected to rise to $41.08 by 2027, a +13% move from its current price of $36.40. IDYA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $35.53 | $36.40 | $37.29 | -0.01% |
| Aug 2 | $35.17 | $36.39 | $37.66 | -0.02% |
| Aug 3 | $34.90 | $36.39 | $37.95 | -0.03% |
| Aug 4 | $34.67 | $36.39 | $38.19 | -0.04% |
| Aug 5 | $34.47 | $36.38 | $38.40 | -0.05% |
| Aug 6 | $34.29 | $36.38 | $38.60 | -0.06% |
| Aug 7 | $34.12 | $36.38 | $38.78 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $34.12 | $36.38 | $38.78 | -0.07% |
| Week 2 | $33.21 | $36.35 | $39.79 | -0.13% |
| Week 3 | $32.52 | $36.33 | $40.58 | -0.20% |
| Week 4 | $31.94 | $36.30 | $41.26 | -0.27% |
| Week 5 | $31.44 | $36.28 | $41.86 | -0.33% |
| Week 6 | $31.00 | $36.25 | $42.41 | -0.40% |
| Week 7 | $30.59 | $36.23 | $42.91 | -0.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
IDEAYA Biosciences, Inc. is a healthcare company focused on precision medicine for oncology. It develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
The company’s pipeline includes Darovasertib, an oral PKC inhibitor studied for uveal melanoma and ocular cancer in monotherapy and in combination with crizotinib, along with IDE849, IDE034, IDE161, IDE705, IDE397, IDE892, IDE574, and IDE275 across various cancer targets. IDEAYA also pursues preclinical research programs and offers discovery platforms, and it maintains strategic alliances with GlaxoSmithKline, Pfizer, Gilead, Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals, and Les Laboratoires Servie. Clinical collaborations include AstraZeneca to evaluate IDE849 and Roche to evaluate IDE892.
IDEAYA was incorporated in 2015 and is headquartered in South San Francisco, California.
IDEAYA Biosciences, Inc. (IDYA) trades in the Healthcare sector with a current price of $35.93 and a market cap of $3.46B, ranking 1636. The stock has a 30-day trading range from $29.98 to $43.05, with near-term support at $27.60 and resistance at $40.51.
The market exhibits bullish near-term sentiment, supported by a price oscillating around key moving averages (SMA50 $31.87; SMA200 $32.25) and a 50% implied volatility profile.
A major floor 26.5% below — a decisive break under it would weaken the trend.
The nearest floor, 14.2% below — buyers have tended to step in here.
The nearest ceiling, 11.3% above — a clean break opens room to run.
A major ceiling 24.5% above — clearing it would confirm fresh momentum.
Key IDYA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IDYA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $36.06 | Buy | $36.09 | Buy |
| MA 10 | $35.90 | Buy | $36.10 | Buy |
| MA 20 | $36.71 | Sell | $35.88 | Buy |
| MA 50 | $33.35 | Buy | $34.31 | Buy |
| MA 100 | $32.27 | Buy | $33.10 | Buy |
| MA 200 | $32.69 | Buy | $31.71 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.20 | Neutral |
| Stoch RSI (14) | 57.67 | Neutral |
| CCI (20) | -21.68 | Neutral |
| Williams %R (14) | -20.90 | Info |
| MACD (12,26,9) | -0.27 | Sell |
| ROC (12) | -0.68 | Sell |
| Bollinger %B (20,2) | 0.44 | Neutral |
| Stochastic %K (14) | 79.10 | Neutral |
| TRIX (15) | 0.37 | Buy |
| Awesome (5,34) | 0.66 | Buy |
| Ultimate (7,14,28) | 52.43 | Neutral |
| Momentum (10) | 0.47 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 36.23 | Buy |
| ADX (14) | 14.98 | Neutral |
| ATR (14) | 0.82 | Info |
Near-term technical picture favors a bullish tone, with RSI at 50 and the price trading above both SMA50 ($31.87) and SMA200 ($32.25). The current price of $35.93 sits above these moving averages, suggesting upside potential in the near term. The 30-day range spans $29.98 to $43.05, reflecting volatility, while support sits at $27.60 and resistance at $40.51.
The stock’s annualized volatility runs around 50%, indicating meaningful risk alongside the upside.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $27.60 | $36.40 | $45.32 | 0% | Neutral | |
| $33.10 | $41.08 | $53.69 | +13% | Neutral | |
| $35.42 | $45.06 | $60.91 | +24% | Bullish | |
| $40.63 | $52.75 | $73.21 | +45% | Bullish | |
| $50.26 | $66.43 | $94.27 | +83% | Bullish | |
| $53.66 | $72.08 | $104.29 | +98% | Bullish | |
| $56.92 | $77.61 | $114.27 | +113% | Bullish | |
| $60.78 | $84.05 | $125.72 | +131% | Bullish | |
| $62.44 | $87.51 | $132.81 | +140% | Bullish | |
| $67.39 | $95.65 | $147.14 | +163% | Bullish | |
| $99.19 | $149.10 | $242.73 | +310% | Bullish | |
| $193.55 | $320.67 | $567.26 | +781% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $27.60 | $36.40 | $42.44 | +0.00% |
| August 2026 | $30.95 | $36.24 | $43.35 | -0.45% |
| September 2026 | $30.59 | $36.09 | $43.69 | -0.42% |
| October 2026 | $31.28 | $37.12 | $45.36 | +2.85% |
| November 2026 | $31.43 | $37.48 | $46.15 | +0.97% |
| December 2026 | $30.52 | $36.55 | $45.32 | -2.46% |
Click any year to see its month-by-month IDYA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect IDYA to range from $27.60 to $45.32 through 2026. The $36.40 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The IDYA price prediction for 2027 points to an average of $41.08 (low $33.10, high $53.69) — a potential gain of +13% on today's $36.40. A consolidation phase looks the most probable path here.
In 2028, IDYA is projected to trade between $35.42 and $60.91, averaging $45.06 — a potential gain of +24% from today's $36.40. That is up +10% on the projected 2027 average. Momentum favours further upside here.
IDEAYA Biosciences, Inc.'s 2029 outlook centres on $52.75, within a $40.63 to $73.21 range. That is up +17% on the projected 2028 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, IDYA could reach as high as $94.27, with a base case around $66.43 and support toward $50.26 — roughly +83% from $36.40. Momentum favours further upside here.
Expect IDYA to range from $53.66 to $104.29 through 2031. The $72.08 average target implies a +98% move from current prices. That is up +9% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The IDYA price prediction for 2032 points to an average of $77.61 (low $56.92, high $114.27) — a potential gain of +113% on today's $36.40. Momentum favours further upside here.
In 2033, IDYA is projected to trade between $60.78 and $125.72, averaging $84.05 — a potential gain of +131% from today's $36.40. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
IDEAYA Biosciences, Inc.'s 2034 outlook centres on $87.51, within a $62.44 to $132.81 range. That is up +4% on the projected 2033 average. That marks a +140% change versus current levels. Momentum favours further upside here.
By 2035, IDYA could reach as high as $147.14, with a base case around $95.65 and support toward $67.39 — roughly +163% from $36.40. Buyers look set to stay in control over this stretch.
Expect IDYA to range from $99.19 to $242.73 through 2040. The $149.10 average target implies a +310% move from current prices. That is up +56% on the projected 2035 average. Momentum favours further upside here.
The IDYA price prediction for 2050 points to an average of $320.67 (low $193.55, high $567.26) — a potential gain of +781% on today's $36.40. Buyers look set to stay in control over this stretch.
Investing $1,000 in IDYA today (≈ 27.472527 IDYA) could be worth
$8,809.62
+$7,809.62 (+781%) by 2050 · US Dollar
Based on the average projected IDYA price of $320.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IDYAwould be worth at today's price.
$1,000 invested in IDYA on Jul 30, 2025 (≈ 39.447731 IDYA) would be worth
$1,435.9
+$435.9 (+43.6%) today · 1.44× · US Dollar
Based on a IDYA entry price of $25.35 vs. today's $36.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $36.23 | $1,004.69 | +0.5% |
| 1 month ago | $37.27 | $976.66 | -2.3% |
| 3 months ago | $28.19 | $1,291.24 | +29.1% |
| 6 months ago | $32.19 | $1,130.79 | +13.1% |
| 1 year ago | $25.35 | $1,435.9 | +43.6% |
| All time (5.0y) ago | $23.47 | $1,550.92 | +55.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IDYA forecast.
Our base-case forecast reaches $73.00 around 2032.
Implied market cap at $73.00: $7.03B
The multi-year forecast shows substantial upside beyond 2026. For 2030, the model projects an average price of $66.25 with a max of $96.41 and a min of $49.08, an implied ROI of 84.4% and a bullish sentiment. By 2040, the average rises to $141.77 with a max of $239.85 and a min of $90.36, delivering about 294.6% ROI.
In 2050, the average is forecast at $308.12 with a max of $570.52 and a min of $174.83, implying roughly 757.5% ROI and a bullish stance. The trajectory from 2026 through 2050 reflects a clear upward path in the forecast, but these are estimates and not guarantees, and market conditions can alter outcomes. Drivers and risks are not specified in the numbers provided; investors should weigh the sizable upside against inherent market volatility and uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows min $49.08, avg $66.25, max $96.41 with an ROI of 84.4% and a bullish sentiment.
Long-term forecasts show increasing average prices from 2026 ($35.93) through 2030 ($66.25), 2040 ($141.77), and 2050 ($308.12), with rising ROIs (84.4%, 294.6%, 757.5%). These are estimates, not guarantees.
No. The 2030 maximum forecast is $96.41, which is below $100.
For 2040, the min is $90.36, the avg is $141.77, and the max is $239.85, with an ROI of 294.6% and bullish sentiment.
The 2026 forecast shows min $27.60, avg $35.93, max $44.53, ROI 0%, and neutral sentiment.
IDEAYA Biosciences, Inc. Community Discussion
0Share your IDEAYA Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.